Senator Alquist's “Superbug” Legislation Passes the Senate Floor

Legislation will establish MRSA screening, tracking, and prevention

SACRAMENTO— Legislation by Senator Elaine Alquist (D – San Jose) to help prevent the spread of the “superbug” known as MRSA and other hospital acquired infections passed the Senate on a 30-9 bipartisan vote.

“I am very pleased that the Senate recognized the value of addressing the MRSA and hospital acquired infection public health epidemic,” stated Alquist. “Hospitals and patients need to know where infection hot spots are so that we can protect against potentially dangerous situations.”

A bacterial infection resistant to most common antibiotics, MRSA (methicillin-resistant Staphylococcus aureas) can often look like an infected bug bite or scratch but left untreated, it can turn deadly or severely debilitating resulting in paralysis. In many cases, recovery can take several months and require IV antibiotics.
Senator Alquist’s legislation, SB 1058, has six major components:

* Infection Control Procedures – Requiring hospitals to implement procedures for identifying patients who are infected with MRSA such as detecting MRSA hotspots inside a hospital such as an ICU;

* Screening – Requiring hospitals to screen high-risk patients upon admission for MRSA so that other patients are protected;

* Enhanced Infection Prevention Protocols -- Requiring hospitals to follow enhanced protocols to protect against the spread of MRSA and other hospital acquired infections such as cleaning and disinfecting, among other items, all televisions, telephones, bedding, elevators, meeting rooms, glucometers, gurneys, feeding pumps, and cardiac monitors;

* Reporting – Requiring hospitals to report MRSA and other infection data to the state Department of Public Health (DPH);

* Public Disclosure – Requiring DPH, by 2011, to begin publishing infection data on its website; and

* Infection Control Staffing – Requiring hospitals to employ one infection control professional for every 100 licensed beds.

“People who go to the hospital should be safe from the threat of infection and today they are not,” Alquist added.
Hospital acquired infections have increased dramatically in recent years. Since the mid-1970s, there has been a 30-fold increase in MRSA in our hospitals. Staph-related deaths nationally, once a rarity, are approaching 20,000 annually, more than the number of AIDS deaths every year, and this number grows every year. Some 95,000 cases of serious MRSA infections are reported annually.

The Center for Disease Control (CDC) estimates that every year two million patients contract a hospital acquired infection while being treated for something else, and almost 100,000 die every year from these infections.Visit Senators site

Click to buy sinofresh products from its own store
www.sinofreshstore.com.

[video] Charles Fust, CEO of SinoFresh HealthCare Discusses Preliminary Test Results From In Vivo Pilot Study on WallSt.net's 3-Minute Press Show

VENICE, Fla., Aug. 21 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc. (OTC Bulletin Board: SFSH - News), a developer and marketer of innovative upper respiratory system therapies, today announced that the company's CEO, Charles Fust, is featured in an exclusive interview on WallSt.net's 3-Minute Press Show.The interview gives viewers an overview of the company, and the significance of the company's latest press release.

To view the clip in its entirety, visit:
http://www.tv.wallst.net/r/3-minute-press/Charles-Fust-SFSH/215/902
About SinoFresh HealthCare, Inc:

SinoFresh HealthCare, Inc. (OTC BB: SFSH.OB - News) is a developer and marketer of innovative upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh® Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh® products are available in major retail outlets nationwide. More information is available at http://www.sinofreshstore.com/

StockGuru.com Announces a New Executive Interview With Charles A. Fust of SinoFresh Healthcare Inc

FRISCO, Texas, Aug. 11, 2008 (PRIME NEWSWIRE) -- John Pentony, Publisher of Stockguru.com, announced today that the company has posted a new Podcast Interview featuring Charles A. Fust, Founding Chairman and CEO of SinoFresh Healthcare (OTC BB:SFSH.OB - News). SinoFresh HealthCare is a developer and marketer of innovative, patented upper respiratory system therapies. The company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial and fungal organisms that are suspected to cause pathogenesis of the mouth, nose and throat. The company's lead product, SinoFresh(tm) Nasal and Sinus Care, is a hygienic cleansing spray that kills germs and removes other nasal-sinus irritants. The company is also researching how antiseptic cleansing may alleviate chronic sinus distress, a condition that may affect 37 million Americans annually. SinoFresh(tm) products are available online at www.sinofreshstore.com.

To listen to the StockGuru.com interview with Charles A. Fust of SinoFresh Healthcare, please visit:

http://www.stockguru.com/index.php?id=67 (Copy and paste link into Web Browser)

SinoFresh Nasal Spray Kills MRSA 'Super-Bug' in Live Noses

VENICE, Fla., Aug. 19 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc., (OTC Bulletin Board: SFSH - News) announced preliminary results today from a successful in vivo pilot study indicating that its patented SinoFresh® nasal spray was shown to be useful in controlling the MRSA "super-bug" in the nasal passages. This study utilized a recognized scientific model intended to demonstrate SinoFresh® nasal spray's ability to kill MRSA hiding in the nasal passages. These favorable efficacy results follow an earlier, successful in vitro study that was conducted at the Public Health Research Institute under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis Center and Hospital Infections Program.

The study showed that "SinoFresh® nasal spray used three times daily appeared to effectively eliminate MRSA in the noses of the test animals while leaving enough normal microbes to keep a normal population in the nasal passages," according to Dr. John Todhunter, consultant to SinoFresh, who oversaw the study conducted at Virion Systems in Rockville, MD.

MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a growing concern in the health care community. It incubates in the nasal passages and then gets on the skin where it can cause severe, virulent infections. The effect of MRSA can lead to disfigurement and sometimes death. MRSA is also highly antibiotic resistant, making MRSA infections difficult to treat. It is believed that approximately 2 - 3 million persons in the U.S. walk around carrying MRSA in their nasal passages at any time and elimination or severe reduction of nasal MRSA colonies is seen as a potentially important weapon in fighting the spread of MSRA. The antibiotic Mupirocin is currently used to reduce nasal MRSA loads.

SinoFresh® nasal spray attacks MRSA in the nasal passages by destroying the "super-bug's" cell walls and membranes by physical means rather than by an antibiotic mechanism involving attack on the metabolism of the microbes as occurs with the use of antibiotics. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics the chances for development of resistance to SinoFresh® Nasal Spray's mode of killing them is much lower said Dr. Todhunter."

According to William Wilferth, VP for Research and Development at SinoFresh, "These results have exceeded our expectations. The positive results of this in vivo study gives us the solid scientific platform we have needed in order to advance our efforts to fight MRSA to the next level."

Charles Fust, CEO of SinoFresh, noted that the data reported is extremely encouraging and that there is a significant market need for new methods to address MRSA control which is believed to be as many as 80 to 100 million treatments annually in the United States alone.

Click to buy sinofresh products from its own store
www.sinofreshstore.com.

SINOFRESH TO STUDY ANTIBACTERIAL BENEFITS OF NASAL CLEANSING SPRAY IN HORSES

SinoFresh HealthCare, Inc. today announced that it will embark on a program to study the ability of its nasal spray, SinoFresh™ Nasal Mist, to protect horses against colonization with methicillin resistant Staphylococcus aureus (MRSA) bacteria. Scott Weese, DVM, of the Department of Clinical Studies at the, Ontario Veterinary College, University of Guelph, will direct the studies in collaboration with SinoFresh. These studies follow positive results of previously reported in vitro experiments showing efficacy against MRSA.

MRSA derives its name from its resistance to common antibiotics. It is a major concern for human infection in hospitals and long-term care facilities where elderly and immunocompromised patients are especially susceptible. MRSA is also a critical issue with veterinarians and animal breeders where overuse of antibiotics can lead to disease. MRSA colonization frequently occurs in the mucous membranes of the nose.

“MRSA has emerged as an important problem in animals, particularly horses and dogs. Our main concerns are the potential for animals to develop serious diseases, and the possibility of animal-to-human transmission,” explained Dr. Weese. “We’re excited to work with SinoFresh, and the potential of its nasal spray to address MRSA in animals without facilitating further resistance.”

“With concern over antibiotic resistant Staphylococcus aureus rising among researchers worldwide, we are encouraged by this higher level of scientific evaluation,” stated Charles Fust, Chairman and CEO of SinoFresh. “We have long held the notion that our innovative research efforts, spanning more than eight years, hold great promise in this particular arena.” Click to know more on MRSA

Visit Sinofreshstore

SinoFresh Announces Next Step in Program to Attack Super-Bug MRSA

VENICE, FL-- On the heels of the recent announcement stating a commitment to develop a product to attack MRSA -- the so-called "super bug," SinoFresh HealthCare, Inc. (OTC BB:SFSH.OB - News) announced today the continuation of a series of development activities to implement that commitment. This is a study, which will be in the lab phase by the end of July 2008, and according to Dr. John Todhunter, an outside consultant to SinoFresh, "is expected to give robust proof of concept for the nasal formulation designed to kill MRSA hiding in the nose."

The SinoFresh formulation evolves from a well-established antimicrobial agent which is classed by FDA as "generally recognized as safe and effective" and has been used in other applications for a number of years. The present study follows an in vitro study conducted at Public Health Research Institute under the direction of Dr. Barry Kreiswirth who heads the institute's Tuberculosis Center and Hospital Infections Program, and will be an in vivo study using a well validated model reflecting demonstrated results relative to MRSA colonizing in the human nose. "Efficacy has been proven in a 'test tube' and now we're moving to show MRSA killing properties in a living nose," said Dr. Todhunter, President of SRS International.

MRSA (which stands for methicillin resistant Staphylococcus aureus) is a growing concern in the health care community. It hides in the nasal passages and then gets on the skin where it can cause severe, virulent infections which can lead to disfigurement and sometimes death. It is also highly antibiotic resistant which makes MRSA infections difficult to treat.

According to Dr. Todhunter there is an apparent consensus in the health care community that having a high nasal load of MRSA is associated with increased rates of MRSA infection. Eradication of nasal MRSA colonies is seen as a potentially important weapon in reducing the spread of MRSA. The antibiotic Mupirocin is currently the treatment of choice for reducing nasal MRSA loads. It has become less effective as MRSA resistance to it has emerged. SinoFresh's approach to killing MRSA in the nasal passages is based on the potent ability of the SinoFresh active ingredient as an antimicrobial which destroys bacterial cell walls and membranes. This happens by physical means rather than by an effect on bacterial metabolism which is how antibiotics work. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics, the chances for development of resistance to SinoFresh's nasal formulation is much lower," said Dr. Todhunter.

According to William Wilferth, VP for Research and Development at SinoFresh, "We stated earlier we were going to be very aggressive in the pursuit of MRSA solutions. Our commitment in launching this most recent in vivo study moves us further down that path." Charles Fust, CEO of SinoFresh HealthCare, Inc., stated, "I remain cautiously optimistic in light of published statements on the topic of MRSA, exampled by, the average incremental cost per patient with an acquired infection is $15,275 multiplied by at least 2,000,000 infections indicating possible cost to hospitals of $30.5B, [Clinical Infectious Diseases (v. 36, 2003) 1424-1432], suggests a potentially rewarding market receptive to new alternatives."

Visit Sinofreshstore